Gastrointestinal hormones in clinical medicine.
Information concerning GEP hormones has progressively advanced since the initial discovery of a GEP hormone, secretin, in 1902. Studies in this area flourished with the advent of radioimmunoassay, and have provided an understanding of the secretion, regulation, metabolic actions, and role in certain diseases of major GEP hormones. Measurement of GEP hormones has achieved importance in clinical medicine and allowed understanding of the pathophysiology of several clinical disorders. The decade to come should witness additional advances in this rapidly expanding field.
D055598:Chemical Phenomena; D002621:Chemistry; D002766:Cholecystokinin / Q000502:physiology; D003920:Diabetes Mellitus / Q000209:etiology; D003967:Diarrhea / Q000209:etiology; D004700:Endocrine System Diseases / Q000150:complications; D005749:Gastric Inhibitory Polypeptide / Q000502:physiology; D005755:Gastrins / Q000502:physiology; D005768:Gastrointestinal Hormones / Q000502:physiology* / Q000627:therapeutic use; D005934:Glucagon / Q000502:physiology; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology; D009037:Motilin / Q000502:physiology; D009369:Neoplasms / Q000150:complications; D009496:Neurotensin / Q000502:physiology; D010191:Pancreatic Polypeptide / Q000502:physiology; D010437:Peptic Ulcer / Q000209:etiology; D012633:Secretin / Q000502:physiology; D012871:Skin Diseases / Q000209:etiology; D013004:Somatostatin / Q000502:physiology; D013373:Substance P / Q000502:physiology; D014660:Vasoactive Intestinal Peptide / Q000502:physiology
D005755:Gastrins; D005768:Gastrointestinal Hormones; D012633:Secretin; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin; D013004:Somatostatin; D009037:Motilin; D005749:Gastric Inhibitory Polypeptide; D010191:Pancreatic Polypeptide; D005934:Glucagon; D002766:Cholecystokinin